⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413514 | 1.00 | — | — | |
| SCHEMBL17413569 | 1.00 | — | — | |
| SCHEMBL16263046 | 1.00 | — | — | |
| SCHEMBL17413513 | 1.00 | — | — | |
| SCHEMBL14984934 | 1.00 | — | — | |
| SCHEMBL16838131 | 0.83 | — | — | |
| SCHEMBL14984916 | 0.83 | — | — | |
| SCHEMBL22520331 | 0.81 | — | — | |
| SCHEMBL17125420 | 0.81 | — | — | |
| SCHEMBL15315749 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20150141399-A1 | MEK Inhibitors And Methods Of Their Use | EXELIXIS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070930-A1 | Pyrimidine and Pyrazine Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008024980-A2 | PYRROLE, THIOPHENE, FURAN, IMIDAZOLE, OXAZOLE, AND THIAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024974-A1 | PYRIMIDINE AND PYRAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024961-A1 | DIHYDROPYRIDAZINE, TETRAHYDROPYRIDINE, CHROMANONE, AND DIHYDRONAPHTHALENONE DERIVATIVES AS HEAT-SHOCK PROTEIN 90 INHIBITORS | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024970-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |